Detection Of K-ras Gene Mutation In Breast Cancer

Objective As EGFR inhibitor, Cetuximab has been widely used in several solid tumors,and has perfect therapeutic effect and security.Breast Cancer is the commonest malignant epithelial tumor for women.Breast Cancer also has high expression of EGFR.But there are few studies on Cetuximab for treating Breast Cancer.Therefore we detected K-ras gene mutation state and mutation type in Breast Cancer,and investigated the possibility of using Cetuximab in Breast Cancer.Methods 25 Breast Cancer specimens were collected from patients with Breast Cancer in FuJian provincial hospital from June 2009 to March 2010.These specimens were DNA sequenced by pyrosequencing technology in order to detect K-ras gene mutation state and mutation type.Specific procedures:1.Ebed and Slice;2.Extract genome DNA;3.Synthesize primer;4.DNA Proliferate by PCR;5.Sequence DNA;6.Determine results: If bases in codon 12 and 13 were GGT and GGC,we considerd K-ras gene as wild-type.If any base mutation in codon 12 and 13,we consider K-ras gene as mutation-type.Results In all specimens that detected , codon 12 and 13 in K-ras gene were wild-type.Conclusions 1.Mutation rate of K-ras in Breast Cancer is tiny.This indicate that K-ras signal pathway is one of stable pathways of Breast Cancer and Cetuximab is probable benefit for most of Breast Cancer patients.2.As one of EGFR pathway ,K-ras gene were wild-type expression.It is considered that Cetuximab is probable becoming a promising treatment for Breast Cancer and Cetuximab combined chemical therapy will be a trend for Breast Cancer treatment in the future.3.As the stable expression of K-ras pathway,Cetuximab is possible to combine with different targeted therapy medicines for all types of Breast Cancer.Combined therapy that attacked multiple targets is a attractive strategy.